✦ LIBER ✦

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

✍ Scribed by Nichita, Cristina; Stelle, Marc; Vavricka, Stephan; El-Wafa Ali, Abdou; Ballabeni, Pierluigi; de Saussure, Philippe; Straumann, Alex; Rogler, Gerhard; Michetti, Pierre

Book ID: 120583828
Publisher: S. Karger AG
Year: 2010
Tongue: English
Weight: 143 KB
Volume: 81
Category: Article
ISSN: 0012-2823
DOI: 10.1159/000253855

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P132 - Clinical experience with adalimum

P132 - Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease

✍ C.M. Nichita; M. Stelle; S. Vavricka; A.A. El Wafa; P. De Saussure; A. Straumann 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 47 KB

W1223 Clinical Experience with Adalimuma

W1223 Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease

✍ Nichita, Cristina; Stelle, Marc; Vavricka, Stephan R.; El-Wafa, Ali Abdou; De Sa 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Clinical experience with infliximab and

Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease

✍ Riis, Åse; Martinsen, Tom C.; Waldum, Helge L.; Fossmark, Reidar 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 166 KB

The Italian clinical experience with ada

The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases

✍ Maria Laura Annunziata; Fabrizio Bossa; Rosamaria Bozzi; Flavio Caprioli; Andrea 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 170 KB

T1055 Post Marketing Clinical Experience

T1055 Post Marketing Clinical Experience with Adalimumab in Crohn's Disease

✍ Mardini, Houssam E.; Bryson, Ben; Flomenhoft, Deborah R.; Arsenescu, Razvan I.; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Adalimumab safety in global clinical tri

Adalimumab safety in global clinical trials of patients with Crohn's disease

✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr